TinyGemsBreaks Archive - Page 2 of 99

ThursdayApr 04, 2024 3:15 pm

TinyGemsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Delivers Significant Growth to Top Line Revenue

Knightscope (NASDAQ: KSCP), an innovator in robotics and artificial intelligence (“AI”) technologies focused on public safety, is celebrating its 11th anniversary of its founding in 2013 with a total of 18 contracts for new business along with five renewal agreements valued at over $1 million. “Building on the success of its first Innovation Week and the recently announced 2023 Financial Performance Highlights, Knightscope delivers significant growth to its top line revenue with these latest contracts. Fast-growing markets such as transportation, healthcare, education and local government represent the majority of these contracts and account for many more future opportunities to expand…

ThursdayApr 04, 2024 2:22 pm

TinyGemsBreaks – Vision Marine Technologies Inc. (NASDAQ: VMAR) Marks Strategic Milestone in Industrialization of High-Tension Battery Packs

Vision Marine Technologies Inc. (NASDAQ: VMAR), a leader in electric marine propulsion, today announced the commissioning of its partner Neogy, a subsidiary of Startek Energy Group, state-of-the-art lithium battery production facility in Pompignac, France. According to the announcement, this pivotal development marks a significant milestone in the industrialization of high-tension battery packs designed specifically for Vision Marine’s innovative electric boating solutions. “The use of HV batteries in the nautical industry demands a very high level of safety and mastery of the technology,” said Xavier Montagne, CTO of Vision Marine. “It’s not just a matter of designing the right battery but…

TuesdayApr 02, 2024 3:56 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives New Epilepsy, Anti-Viral Agent Patents

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has received three new patent awards. According to the announcement, the company was awarded two new patents in its epilepsy patent family; both awards were granted in the United States. The U.S. patents, which cover both swallowed capsules and dissolvable oral tablets, complement research indicating DehydraTECH-CBD has potential to decrease epileptic seizures in rodents and to be absorbed into the bloodstream more effectively than the current treatments. In addition, Lexaria was awarded a patent in Japan in is antiviral agent patent family. The new patents bring the total of…

TuesdayApr 02, 2024 3:14 pm

TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Enters Acquisition Agreement to Acquire Biodefense Vaccine Developer

Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, has signed a definitive arrangement agreement to acquire Appili Therapeutics Inc. (TSX: APLI) (OTCQX: APLIF). Appili is a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. According to the agreement, Adivir Inc., a wholly owned subsidiary of Aditxt, will acquire all issued and outstanding Class A common shares of Appili. Assets acquired by Aditxt will include FDA-approved LIKMEZ(TM), which is the ATI-1701 tularemia vaccine defense program, and the ATI-1801 topical formulation. “The acquisition of Appili would represent another step in Aditxt’s journey towards…

TuesdayApr 02, 2024 1:47 pm

TinyGemsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Preclinical Data Supporting NPRL2 Gene Therapy

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced that its research collaborators have published positive preclinical data for the NPRL2 tumor suppressor gene, utilizing Genprex’s non-viral Oncoprex(R) Delivery System, in KRAS/STK11 mutant anti-PD1 resistant non-small cell lung cancer (“NSCLC”) in a humanized mouse model. “These positive preclinical data are very encouraging and support NPRL2 gene therapy as a potential treatment for a sub-group of NSCLC in which patients traditionally are resistant to existing therapies,” said Rodney Varner, president, chairman and CEO at Genprex. “We…

TuesdayApr 02, 2024 1:10 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases FY 2023 Financial Report, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has released financial results for the full year ending Dec. 31, 2023; the company also reported on corporate and clinical development achievement for the year. Highlights of the report included that Berubicin, the company’s lead program, has passed preplanned interim futility analysis milestones with a recommendation to proceed without modification into a potentially pivotal glioblastoma multiforme (“GBM”) study, and enrollment for the Berubicin study has been completed with topline data expected in first half…

MondayApr 01, 2024 3:57 pm

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Announces FTZ Filing as ‘Strategic Initiative’

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has filed for Foreign Trade Zone (“FTZ”) status with the U.S. Department of Commerce; the company is filing for the status at its commercial vehicle manufacturing and assembly center in Tunica, Mississippi. According to the announcement, the company anticipates that FTZ status would provide key benefits, including the opportunity for improving company cash flow through reduction of taxes, fees and deferment of import duties. Specifically, Mullen projects that deferred working capital on domestic sales could result in deferred capital outlays of $10 million for the remainder of fiscal year 2024.…

MondayApr 01, 2024 3:44 pm

TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q4, FY 2023 Financial Report, Operational Update

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is reporting financial results and operating highlights for Q4 and full year 2023, for the period ended Dec. 31, 2023. The report noted that revenue came in at $3.2 million for Q4 2023 and $13.8 million for the full year; gross profit was $2.1 million for the Q4 2023 and $8.3 million for the full year; and gross margin totaled 64% for Q4 2023 and 60% for the full year. In addition, the company reported…

MondayApr 01, 2024 3:26 pm

TinyGemsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Year-End 2023 Financial Report, Business Update

Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial-intelligence (“AI”) and machine-learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, is reporting on its financial and operating results for the year ended Dec. 31, 2023; the company also released a corporate update. The report noted POAI experienced a net loss of some $14 million on total revenue of approximately $1.8 million for the year; the company also reported a 50% reduction in basic and diluted net loss per common share for the full year 2023. In…

MondayApr 01, 2024 12:35 pm

TinyGemsBreaks — Cepton Inc. (NASDAQ: CPTN) Releases Q4, FY 2023 Financial Report, Business Update

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, is reporting on its financial and business results for the fourth quarter and full year ending Dec. 31, 2023. The financial report included full-year 2023 revenue of $13.1 million, a 76% increase over the prior year and an increase over the full-year 2023 revenue guidance as well as Q4 2023 product revenue of $2.5 million, an increase of 152% compared to the same period in 2022; the company’s full-year gross margin was 27% with a Q4 2023 gross margin of 54%. Business highlight for the company included its…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (310) 299-1717

TinyGemsBreaks